Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nexavar Well Tolerated in Japanese Renal Cancer Patients
July 7, 2008
- REGULATORY NEWS IN BRIEF
July 7, 2008
- PPIs Drugs of Choice for Dyspepsia Symptoms: J-FOCUS Study
July 7, 2008
- DSP Quickly Expands R&D Pipeline in the Field of Diabetes
July 7, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 7, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 7, 2008
- Bayer Yakuhin to Achieve \200 Bil. Sales in 5 Years
July 7, 2008
- Physician-led Study of Talc to Begin Soon
July 7, 2008
- 16 APIs, Including Adapalene, to Be Approved
June 30, 2008
- Draft Basic Policies 2008 Approved Calling For Maintenance of \1.1 Tril. Cutting Plan
June 30, 2008
- Distribution Practices Must Be Improved to Review FPMAJ's Pricing Reform Proposal: Mr Tsushima
June 30, 2008
- TOPICS／Japanese Society for Treatment of Obesity Inaugurated
June 30, 2008
- Improvements of Distribution Practices Essential for Pricing System Reform: Mr Nagano
June 30, 2008
- Multiparty Group of Diet Members to Discuss Increases in Tobacco Tax
June 30, 2008
- REGULATORY NEWS IN BRIEF
June 30, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 30, 2008
- RNAi Drugs Development Race Heats Up with Entry of Kyowa Hakko
June 30, 2008
- Kyowa Hakko Licenses RNAi Drug for RSV Infection from Alnylam
June 30, 2008
- Annual Meeting of Japanese Society of Chemotherapy
June 30, 2008
- Okayama Univ. to Lead Gene Therapy Research for Prostate Cancer in Asians
June 30, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…